Find a Cancer Provider

Are you a referring physician?
within
I am searching for a
Reset Form
Ronac Mamtani, MD, MSCE

Ronac Mamtani, MD, MSCE Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Languages spoken:

  • Hindi

Dr. Mamtani is employed by Penn Medicine.

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Internal Medicine, 2009
  • Medical Oncology, 2012

Clinical Expertise:

  • Cancer Chemotherapy
  • Immunotherapy
  • Malignant Neoplasm of the Ureter
  • Malignant Tumor of Renal Pelvis
  • Transitional Cell Carcinoma
  • Urachal Cancer
  • Urethral Cancer
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oscar Health Plan of PA
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: State University of New York at Stony Brook
Residency: NewYork-Presbyterian/Weill Cornell Medical Center
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Society of Clinical Oncology (ASCO), National Bladder Cancer Advocacy Network, Scientific Advisory Board, National International Society for Pharmacoepidemiology, International The U.K. Health Improvement Network, Scientific Review Committee, International

Hospital Affiliation

Dr. Mamtani is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Parikh RB, Feld EK, Galsky MD, Adamson BJ, Cohen AB, Baxi SS, Boursi SB, Christodouleas JP, Vaughn DJ, Meropol NJ, Mamtani R.: First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis Future Oncol. : 2019.

Vajravelu RK, Copelovitch L, Osterman MT, Scott FI, Mamtani R, Lewis JD, Denburg MR.: Risk for Chronic Kidney Disease in Patients with Inflammatory Bowel Diseases Increases with Age but is not Associated with 5-aminosalicylate Use Clin Gastroenterol Hepatol pii: S1542-3565 (19): 31245-5,2019.

Corbett CJ, Xia L, Mamtani R, Malkowicz SB, Guzzo TJ.: Survival Benefit Persists With Delayed Initiation of Adjuvant Chemotherapy Following Radical Cystectomy for Locally Advanced Bladder Cancer. Urology 132 : 143-149,2019.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R.: Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer Eur Urol. 76 (4): 524-532,2019.

Margalit O, Mamtani R, Lawrence YR, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.: Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy. Clin Colorectal Cancer 18 (3): 226-230,2019.

Lai Y, Zhong Y, Li H, Patterson K, Hale O, Meng Y, Frenkl TL, Godwin JL, Mamtani R: Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States American Society of Clinical Oncology, Quality Care Symposium, San Diego, CA : 2019.

Parikh R, Adamson B, Galsky M, Khozin S, Baxi S, Cohen A, Mamtani R.: Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer JAMA 322 (12): 1209-1211,2019.

Margalit O, Mamtani R, Kopetz S, Yang YX, Lawrence YR, Abu-Gazala S, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.: Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. Oncologist 24 (8): e671-e676,2019.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R: Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer International Society of Pharmacoepidemiology , Philadelphia, PA : 2019.

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R.: Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. Oncologist. 24 (6): e397-e399,2019.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd

Philadelphia, PA 19147
Phone: (215) 662-7606
Patient appointments: 800-789-7366 (PENN)